PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29939224-4 2019 Methods and results: Concomitant application of PDE3 (cilostamide) and PDE4 (Ro-20-1724) inhibitors increased BKCa unitary channel activity in isolated myocytes from rat coronary arteries. cilostamide 54-65 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 48-52 28389413-11 2017 PDE4 inhibition with Ro-20-1724 (10muM) strongly prolonged the Iso response in LD and HD cells, whereas PDE3 inhibition with cilostamide (1muM) slightly prolonged Iso response only in LD cells. cilostamide 125-136 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 104-108 28687079-8 2017 Cilostamide, a specific inhibitor for PDE3, significantly inhibited the amplitude and frequency of carbachol-enhanced phasic contractions of neonatal rat bladder strips by 38.8% and 12.1%, respectively. cilostamide 0-11 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 38-42 28868120-0 2017 Novel cilostamide analogs, phosphodiesterase 3 inhibitors, produce positive inotropic but differential lusitropic and chronotropic effects on isolated rat atria. cilostamide 6-17 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 27-46 28868120-1 2017 OBJECTIVES: Recently, we showed that some new synthetic compounds structurally related to cilostamide (4-(1,2-dihydro-2-oxoquinolin-6-hydroxy)- N-cyclohexyl-N-methylbutanamide), a selective phosphodiesterase 3 (PDE3) inhibitor, produce inotropic effect comparable to that of IBMX (3-isobutyl-1-methylxanthine), a non-selective PDE inhibitor, but with differential chronotropic effect. cilostamide 90-101 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 190-209 28868120-1 2017 OBJECTIVES: Recently, we showed that some new synthetic compounds structurally related to cilostamide (4-(1,2-dihydro-2-oxoquinolin-6-hydroxy)- N-cyclohexyl-N-methylbutanamide), a selective phosphodiesterase 3 (PDE3) inhibitor, produce inotropic effect comparable to that of IBMX (3-isobutyl-1-methylxanthine), a non-selective PDE inhibitor, but with differential chronotropic effect. cilostamide 90-101 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 211-215 25100281-9 2014 Pretreatment of CCDs with IBMX, a broad-spectrum PDE inhibitor, or cilostamide, a PDE3 inhibitor, abolished the stimulatory effect of ANG II on ROMK channels. cilostamide 67-78 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 82-86 26851245-9 2016 PDE3 inhibition with cilostamide induced an SR Ca(2+) leak, which was also blocked by CaMKII inhibition. cilostamide 21-32 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 0-4 21901315-8 2011 However, CNP increased the 5-HT(4)-mediated inotropic response as well as the beta(1)-adrenoceptor (beta(1)-AR)-mediated response to a similar extent as PDE3 inhibition by cilostamide. cilostamide 172-183 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 153-157 19900965-7 2010 CNP enhanced beta1-AR-mediated increase of cAMP levels to the same extent as the selective PDE3 inhibitor cilostamide and increased beta1-AR-stimulated protein kinase A activity, as demonstrated by increased PLB and troponin I phosphorylation. cilostamide 106-117 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 91-95 20196107-6 2010 In this order of potency, the PDE inhibitors Sildenafil (PDE5) > EHNA (PDE2) > Rolipram (PDE4) > Cilostamide (PDE3) all dilated isolated third generation PA after pre-constriction with the thromboxane analog U46619. cilostamide 106-117 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 119-123 16556871-5 2006 Selective inhibition of PDE3 by cilostamide and PDE4 by Ro 20-1724 potentiated beta1-AR cAMP signals, whereas Glu-R cAMP was augmented only by PD4 inhibition. cilostamide 32-43 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 24-28 19758418-13 2009 Cilostamide, a specific PDE3 inhibitor, corrected the decreased response to an NO donor in isolated aorta from cirrhotic rats, suggesting that the difference in response to NO donors was due to differences in PDE3-induced hydrolysis of cGMP or to cGMP-induced inhibition of PDE3, rather than to differences in PDE5 contribution. cilostamide 0-11 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 24-28 19758418-13 2009 Cilostamide, a specific PDE3 inhibitor, corrected the decreased response to an NO donor in isolated aorta from cirrhotic rats, suggesting that the difference in response to NO donors was due to differences in PDE3-induced hydrolysis of cGMP or to cGMP-induced inhibition of PDE3, rather than to differences in PDE5 contribution. cilostamide 0-11 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 209-213 19758418-13 2009 Cilostamide, a specific PDE3 inhibitor, corrected the decreased response to an NO donor in isolated aorta from cirrhotic rats, suggesting that the difference in response to NO donors was due to differences in PDE3-induced hydrolysis of cGMP or to cGMP-induced inhibition of PDE3, rather than to differences in PDE5 contribution. cilostamide 0-11 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 209-213 19652884-5 2009 The phosphodiesterase-3 (PDE3) inhibitors cilostamide and cilostazol, and the adenylate cyclase activator forskolin, inhibited collagen-induced Akt phosphorylation at Ser473. cilostamide 42-53 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 4-23 19652884-5 2009 The phosphodiesterase-3 (PDE3) inhibitors cilostamide and cilostazol, and the adenylate cyclase activator forskolin, inhibited collagen-induced Akt phosphorylation at Ser473. cilostamide 42-53 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 25-29 18369156-6 2008 Inhibition of PDE4 (with 10 micromol/L Ro 20-1724) increased the amplitude and dramatically slowed down the onset and recovery of cAMP signals, whereas PDE3 blockade (with 1 micromol/L cilostamide) had a minor effect only on subsarcolemmal cAMP. cilostamide 185-196 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 152-156 18846035-7 2008 The inotropic effect was increased by non-selective PDE inhibition (IBMX, 10 microM) and selective inhibition of PDE3 (cilostamide, 1 microM), but not of PDE2 (EHNA, 10 microM) or PDE4 (rolipram, 10 microM). cilostamide 119-130 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 113-117 16678154-5 2006 The relaxations induced by cilostamide (a selective PDE3 inhibitor) and 8-bromo-cAMP (a cell-permeant cAMP analog) were reduced in OLETF rats, as was PKA activity. cilostamide 27-38 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 52-56 15130892-3 2004 The relaxation induced by cilostamide, a selective PDE3 inhibitor, was significantly weaker in superior mesenteric artery rings from STZ-induced diabetic rats than in those from age-matched controls. cilostamide 26-37 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 51-55 16102722-5 2006 The PDE3-specific inhibitor, cilostamide, increased the ratio of apomucin mRNA/18s rRNA, as quantified by real-time RT-PCR. cilostamide 29-40 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 4-8 16424109-11 2006 The specific phosphodiesterase 3 (PDE3) inhibitor cilostamide reversed insulin antilipolysis completely, but did not significantly affect GE antilipolysis. cilostamide 50-61 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 13-32 16424109-11 2006 The specific phosphodiesterase 3 (PDE3) inhibitor cilostamide reversed insulin antilipolysis completely, but did not significantly affect GE antilipolysis. cilostamide 50-61 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 34-38 12007579-6 2002 PDE3 (cilostamide-sensitive), PDE4 (rolipram-sensitive) and PDE5 (zaprinast- and DMPPO-sensitive) isoforms appeared as the main isozymes implicated in the cAMP and cGMP hydrolytic activities. cilostamide 6-17 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 0-4 11673261-3 2001 Cilostamide-sensitive PDE3 was the major activity detected in denuded oocytes, whereas no PDE3 activity could be detected in cumulus cells. cilostamide 0-11 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 22-26 11286810-6 2001 The PDE3 specific inhibitor, OPC3689 (10 and 50 microM), inhibited the growth of SMIE cells (19 and 63%), but not A5 cells. cilostamide 29-36 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 4-8 11368177-6 2001 Furthermore, in genetically obese Zucker rats, an increase in the sensitivity of PDE activity to cilostamide and in the amount of PDE activity immunoprecipitated by an antibody to adipose tissue PDE3 was observed relative to lean littermates. cilostamide 97-108 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 195-199 10807659-1 2000 The effects of cilostamide, a cyclic nucleotide phosphodiesterase 3 (PDE3) selective inhibitor, on vascular intimal hyperplasia were evaluated using a single-balloon injury model and a double-injury model in which the rat common carotid artery was subjected to a second injury at a site injured 14 days previously. cilostamide 15-26 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 69-73 9313930-6 1997 Using cilostamide or Ro 20-1724, we demonstrated that both PDE3 and PDE4 activities were increased following forskolin or 8-bromo-cyclic AMP treatment, with a relatively larger effect observed on PDE3 activity. cilostamide 6-17 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 59-63 12793980-4 2003 The EDHF-type relaxation was enhanced by cilostamide, a PDE3-selective inhibitor, but not by Ro 20-1724, a PDE4-selective inhibitor. cilostamide 41-52 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 56-60 9390636-5 1997 Administration of the PDE3 inhibitors cilostazol or cilostamide together with the PDE4 inhibitor rolipram blocked mitogenic synthesis of DNA, as determined by (3H)-thymidine incorporation into renal cortical DNA, in FA-treated rats. cilostamide 52-63 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 22-26 8894166-9 1996 Relaxation induced by isoprenaline was also potentiated by the cyclic GMP-inhibited PDE (PDE 3) inhibitor cilostamide (100 nM). cilostamide 106-117 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 89-94 19555170-4 2009 The design strategy was based on the structure of cilostamide, a selective PDE3 inhibitor. cilostamide 50-61 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 75-79 33184031-7 2021 In contrast, PDE3 inhibition with cilostamide (1 muM) had no effect on the amplitude of the cAMP transient and a minimal effect on its recovery in SHAM, whereas it potentiated the amplitude and slowed the decay in CH (t1/2off ~ 80 s). cilostamide 34-45 phosphodiesterase 4D, cAMP-specific-like 1 Rattus norvegicus 13-17